The Experts below are selected from a list of 3267 Experts worldwide ranked by ideXlab platform

Michael Thompson - One of the best experts on this subject based on the ideXlab platform.

  • In vitro and in vivo cell-capture strategies using cardiac Stent Technology - A review.
    Clinical biochemistry, 2015
    Co-Authors: Rohan R Ravindranath, Alexander Romaschin, Michael Thompson
    Abstract:

    Stenosis is a symptom of coronary artery disease (CAD), and is caused by narrowing of arteries in the heart. Over the last several decades, medical implants such as cardiac Stents have been developed to counter stenosis. Upon implantation of a Stent to open up a restricted artery, narrowing of the artery can reoccur (restenosis), due to an immune response launched by the body towards the Stent. Currently, restenosis is a major health concern for patients who have undergone heart surgery for coronary artery disease. Recently, there have been new methods developed to combat restenosis, which have shown potential signs of success. One proposed method is the use of Stents to capture cells, thereby reducing immune response. This review will explore the different methods for cell capture both in vitro and in vivo. Biological modifications of the Stent will be surveyed, as well as the use of surface science to immobilize biological probes. Immobilization of proteins and nucleotides, as well as use of magnetic field are all methods that will be further discussed. Finally, concluding remarks and future prospects will be presented.

  • Surface chemical and physical modification in Stent Technology for the treatment of coronary artery disease
    Journal of Biomedical Materials Research Part B: Applied Biomaterials, 2012
    Co-Authors: Feroze Nazneen, Grégoire Herzog, Damien W.m. Arrigan, Noel Caplice, Pasquale Benvenuto, Paul Galvin, Michael Thompson
    Abstract:

    Coronary artery disease kills millions of people every year. It results from a narrowing of the arteries (stenosis) supplying blood to the heart. This review discusses the merits and limitations of balloon angioplasty and Stent implantation, the most common treatment options for coronary artery disease, and the pathophysiology associated with these treatments. The focus of the review is heavily placed on research efforts geared towards the modification of Stent surfaces for the improvement of Stent-vascular compatibility and the reduction in the occurrence of related pathophysiologies. Such modifications may be chemical or physical, both of which are surveyed here. Chemical modifications may be passive or active, while physical modification of Stent surfaces can also provide suitable substrates to manipulate the responses of vascular cells (endothelial, smooth muscle, fibroblast). The influence of micro-and nano-structured surfaces on the in vitro cell response is discussed. Finally, future perspectives on the combination of chemical and physical modifications of Stent surfaces are also presented.

  • surface chemical and physical modification in Stent Technology for the treatment of coronary artery disease
    Journal of Biomedical Materials Research Part B, 2012
    Co-Authors: Feroze Nazneen, Grégoire Herzog, Damien W.m. Arrigan, Noel Caplice, Pasquale Benvenuto, Paul Galvin, Michael Thompson
    Abstract:

    Coronary artery disease (CAD) kills millions of people every year. It results from a narrowing of the arteries (stenosis) supplying blood to the heart. This review discusses the merits and limitations of balloon angioplasty and Stent implantation, the most common treatment options for CAD, and the pathophysiology associated with these treatments. The focus of the review is heavily placed on research efforts geared toward the modification of Stent surfaces for the improvement of Stent-vascular compatibility and the reduction in the occurrence of related pathophysiologies. Such modifications may be chemical or physical, both of which are surveyed here. Chemical modifications may be passive or active, while physical modification of Stent surfaces can also provide suitable substrates to manipulate the responses of vascular cells (endothelial, smooth muscle, and fibroblast). The influence of micro- and nanostructured surfaces on the in vitro cell response is discussed. Finally, future perspectives on the combination of chemical and physical modifications of Stent surfaces are also presented. © 2012 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 2012.

Peter Barlis - One of the best experts on this subject based on the ideXlab platform.

  • In-Stent restenosis associated with Stent malapposition: Seven year optical coherence tomography findings
    International Journal of Cardiology, 2011
    Co-Authors: Maria C. Santos, Tina Lin, Peter Barlis
    Abstract:

    Stent thrombosis and in-Stent restenosis remain significant issues in post-coronary angioplasty care despite advances in anti-platelet therapy and Stent Technology. Angiographic predictors of Stent failure have been proposed, but its precise mechanism has been difficult to elucidate on conventional coronary angiography and intravascular ultrasound due to the low resolution of either approach. Optical coherence tomography (OCT) as a high-resolution intracoronary imaging modality has enabled more detailed insight into the interaction between implanted Stent and underlying endothelium, the evolution of unstable plaque, and the pathogenesis of late lumen loss, affirming its place as an essential tool in the modern-day cardiac catheterisation laboratory. We present a case of in-Stent restenosis seven years after bare-metal Stent insertion, the mechanism of which was gross Stent malapposition as clearly demonstrated on OCT examination.

Ben H. Chew - One of the best experts on this subject based on the ideXlab platform.

  • Innovations in Ureteral Stent Technology.
    The Urologic clinics of North America, 2019
    Co-Authors: Connor M. Forbes, Dirk Lange, Kymora B. Scotland, Ben H. Chew
    Abstract:

    Ureteral Stents are an indispensable tool in contemporary urologic patient care. They have become first-line devices for maintenance of ureteral patency postoperatively and in cases of ureteral narrowing. Despite their widespread use, these implants are associated with multiple complications including Stent colic, infection, and encrustation. There is no ideal ureteric Stent currently available. The aim of most recent Stent innovation has been to make steps toward properties of an ideal Stent. This article reviews recent technological advances in Stent design and how they have attempted to tackle issues that urologists and patients face with ureteral Stents.

  • Update on ureteral Stent Technology
    Therapeutic advances in urology, 2009
    Co-Authors: Dirk Lange, Ben H. Chew
    Abstract:

    Ureteral Stents are commonly used in urology but are frequently associated with patient discomfort, Stent encrustation and Stent-related infection. New biomaterials, coatings and designs have been designed to attempt to reduce these problems. This article reviews coatings to reduce bacterial adhesion and encrustation. In addition, metal ureteral Stents, the triclosan and ketorolac drug eluting ureteral Stents, and biodegradable ureteral Stents are discussed. In summary there is no perfect ureteral Stent that avoids all morbidity but there have been significant advances in the last few years in Stent Technology.

Antonio Colombo - One of the best experts on this subject based on the ideXlab platform.

  • challenges in patients with diabetes improving clinical outcomes after percutaneous coronary intervention through evolving Stent Technology
    Interventional Cardiology Review, 2017
    Co-Authors: Robert A Byrne, Shmuel Banai, Roisin Colleran, Antonio Colombo
    Abstract:

    Patients with diabetes have poorer outcomes after percutaneous coronary intervention than patients without diabetes. The Cre8™ EVO drug-eluting Stent (DES) has design features that aim to improve clinical outcomes in patients with diabetes. These include Abluminal Reservoir Technology - a proprietary polymer-free drug-release system consisting of reservoirs on the abluminal surface of the Stent that control drug release and direct the drug exclusively towards the vessel wall - and the Amphilimus™ drug formulation, which enables enhanced drug-tissue permeation utilising fatty acid transport pathways. The latter is particularly advantageous in patients with diabetes, whose cell metabolism favours increased cellular uptake of fatty acid. Furthermore, evidence suggests that mTOR inhibitors (-limus drugs) utilised in conventional DES are less effective in diabetic cells. The new Stent architecture provides high device deliverability and conformability, facilitating clinical use in complex disease patterns and high-risk lesion morphologies. Clinical evidence for the efficacy and safety of the Cre8™ DES in patients with diabetes has been demonstrated in a number of clinical trials and observational registries. These data are reviewed herein, along with an overview of on-going randomised trials.

  • Drug-Eluting Versus Bare-Metal Stents
    2016
    Co-Authors: Ajay J. Kirtane, Gregg W. Stone, Dean J. Kereiakes, Antonio Colombo
    Abstract:

    Dr. Gregg Stone from Columbia University Medical Center, New York, NY moderated the topic "Drug-Eluting Versus Bare-Metal Stents" with Drs. Antonio Colombo from San Raffaele Scientific Institute and Columbus Hospital, Milan, Italy, Dean Kereiakes from The Christ Hospital Heart and Vascular Center, Cincinnati, OH, and Ajay Kirtane from Columbia University Medical Center/New York-Presbyterian Hospital, New York, NY. The discussion focused primarily on: Advantages, disadvantages, and nuances of drug-eluting and bare-metal Stents; pathophysiology and clinical manifestations of coronary restenosis; evolution from first-generation, drug-eluting Stents to current generation devices; current dual antiplatelet therapy (DAPT) recommendations (especially with regard to DAPT duration); the appropriateness of drug-eluting vs bare-metal Stents for particular patients; and the future of Stent Technology. (Med Roundtable Cardiovasc Ed. 2014;3(4):208–217) ©2014 FoxP2 Media, LLC

  • Newly available and recent advances in drug-eluting Stents
    Expert review of cardiovascular therapy, 2013
    Co-Authors: Charis Costopoulos, Azeem Latib, Toru Naganuma, Alessandro Sticchi, Francesco Giannini, Antonio Colombo
    Abstract:

    The introduction of drug-eluting Stents has revolutionized the treatment of coronary artery disease. First-generation Stents, however, were associated with relatively high revascularization rates and the risk of Stent thrombosis. This has led to a worldwide search for improvements in Stent Technology that will reduce adverse cardiac events following Stent implantation while providing optimal treatment. Here, the authors discuss recent advances in Stent Technology from improvements in Stent platform and Stent polymer to newer mechanisms of drug delivery and the incorporation of proendothelizing agents. The authors also introduce some of the newly available Stents and discuss the evidence associated with their use in clinical practice.

  • Current and future drug-eluting coronary Stent Technology
    Expert review of cardiovascular therapy, 2011
    Co-Authors: Alfonso Ielasi, Azeem Latib, Antonio Colombo
    Abstract:

    Despite the impressive benefits obtained following the introduction of the drug-eluting Stent, safety concerns have been raised over their long-term safety with particular regard to Stent thrombosis. Various mechanisms such as delayed endothelialization, local hypersensitivity and endothelial dysfunction owing to the durable polymer coating and/or the drug itself have been suggested as possible causes of this phenomenon. Therefore, to address these concerns, a newer-generation of drug-eluting Stents has been developed and they are currently undergoing preclinical and clinical evaluation in order to increase both the safety and biocompatibility by optimizing the three major components of drug-eluting Stents: the Stent platform, the polymer and the drug. This article critically reviews the key clinical trials and the current status of these new coronary devices as well as preventing future perspectives for their continued development.

John D. Denstedt - One of the best experts on this subject based on the ideXlab platform.

  • Ureteral Stent Technology: Drug-eluting Stents and Stent coatings.
    Asian journal of urology, 2015
    Co-Authors: Luo Yang, Samantha A. Whiteside, Peter A. Cadieux, John D. Denstedt
    Abstract:

    Ureteral Stents are commonly used following urological procedures to maintain ureteral patency. However, alongside the benefits of the device, indwelling Stents frequently cause significant patient discomfort (pain, urgency, frequency) and can become encrusted and infected. The importance of these sequelae is that they are not only bothersome to the patient but can lead to significant morbidity, urinary retention, ureteral damage, recurrent infections, pyelonephritis and sepsis. When these problems occur, Stent removal or replacement alongside antibiotic, analgesic and/or other symptom-modifying therapies are essential to successfully treat the patient. In an attempt to prevent such morbidity, numerous approaches have been investigated over the past several decades to modify the Stent itself, thereby affecting changes locally within the urinary tract without significant systemic therapy. These strategies include changes to device design, polymeric composition, drug-elution and surface coatings. Of these, drug-elution and surface coatings are the most studied and display the most promise for advancing ureteral Stent use and efficacy. This article reviews these two strategies in detail to determine their clinical potential and guide future research in the area.

  • Current Status of Ureteral Stent Technologies: Comfort and Antimicrobial Resistance
    Current Urology Reports, 2010
    Co-Authors: Carlos E. Mendez-probst, Alfonso Fernandez, John D. Denstedt
    Abstract:

    The placement of a ureteral Stent is one of the most commonly performed urologic procedures. Indwelling ureteral Stents are often accompanied by significant patient morbidity, including lower urinary tract symptoms, flank pain, and urinary tract infections. This article reviews the current state of ureteral Stent Technology developed to address the problem of Stent discomfort and infection.

  • Advances in ureteral Stent Technology.
    World journal of urology, 2000
    Co-Authors: John D. Denstedt, Gregor Reid, Mario Sofer
    Abstract:

    This review focuses on technological advances and relevant research related to ureteral Stents. The importance of physical and chemical biomaterial type, biocompatibility, material coatings such as hydrogels, and infection related to indwelling ureteral Stents are discussed. Recent in vitro and in vivo research has focused on materials that will reduce encrustation and bacterial biofilm formation. The adsorption of antimicrobials onto devices holds promise of reducing infection rates, but multidrug resistant bacteria, short leaching times and adverse side effects make it essential that alternative strategies be investigated. Just so, encrustation limits the long-term use of urinary materials, and a better understanding of factors involved in encrustation are needed to reduce the problem.